Precision Medicine in Oncology®
The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
Latest News
FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors
By Chris Ryan
November 19th 2024
The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
By Kristi Rosa
November 15th 2024
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
